new coronavirus pneumonia
Conditions
Interventions
control group:conventional therapy
Experience group:conventional therapy+tocilizumab
Sponsors
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia; 2. Aged 18 to 85 years; 3. IL-6 elevated (using Elisa method, using the same company kit); 4. Patients or authorized family members volunteered to participate in this study and signed informed consent. Definition of Novel Coronavirus Pneumonia (NCP) clinical cases: 1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever; 2. Critical NCP patient: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission.
Exclusion criteria
Exclusion criteria: 1. Patients who are participating in other drug clinical trials; 2. Pregnant or lactating women; 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50; 4. Definite diagnosis of rheumatic immune-related diseases; 5. Long-term oral anti-rejection or immunomodulatory drugs; 6. Hypersensitivity to tocilizumab or any excipients; 7. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality;Ventilator utilization;Hospitalization day; | — |
Countries
China
Contacts
Public ContactXiaoling Xu
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)
Outcome results
None listed